Stock Analiz

IDXX vs ORKA stock comparison

IDEXX Laboratories vs. Oruka Therapeutics · data as of November 13, 2026

IDEXX Laboratories (IDXX) has a market value of about $55.5B, Oruka Therapeutics (ORKA) about $7.1B.

On our five checks IDEXX Laboratories scores higher: 3.4 out of 5 (good) against 0.4 (weak).

By area, the stronger company is IDEXX Laboratories on future growth; IDEXX Laboratories on track record; IDEXX Laboratories on financial health; IDEXX Laboratories on shareholder returns.

IDEXX Laboratories leads on 9 of the compared lines and Oruka Therapeutics on 1.

Side by side

IDXXORKA
Size and price
Market cap$55.5B$7.1B
Share price$704.23$105.35
Score
Overall score (of 5)3.40.4
Value00
Future growth40
Track record50
Financial health52
Shareholder returns30
Valuation
P/E (TTM)47.5—
Forward P/E44.8—
Price / free cash flow42.6—
Price / sales11.9—
EV / EBITDA33.5—
PEG3.32—
DCF value vs. price−63%—
Business
Revenue$4.7B—
Net income$1.2B-$105M
Free cash flow$1.3B-$88M
Net margin25.4%—
Gross margin (5-yr avg.)60.2%—
ROIC (5-yr avg.)44.1%-22.8%
Growth
Revenue growth (1 yr)10.4%—
Revenue growth (5 yrs, per year)9.7%—
EPS growth (5 yrs, per year)14.3%—
Balance sheet and payouts
Net cash (cash minus debt)-$301M—
Dividend yieldNoneNone
Shareholder yield2.2%0.0%
Analysts
Upside to average target+2%+48%
Consensus ratingBuyStrong buy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: IDXX TTM to September 30, 2026, ORKA FY2025. Not investment advice.

Frequently asked questions

Which is the better stock, IDEXX Laboratories or Oruka Therapeutics?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) IDEXX Laboratories scores 3.4 out of 5 and Oruka Therapeutics 0.4; the table shows where each one is stronger.

Full IDEXX Laboratories analysis → Full Oruka Therapeutics analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.